It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

The US company already sells epilepsy therapy Fycompa (perampanel) and Firdapse (amifampridine) for muscular disease Lambert-Eaton myasthenic syndrome (LEMS) and expects to make revenues of around ...

This month it was Catalyst Pharmaceuticals’ turn to feel the pressure – the company was forced to defend hiking the price of the rare disease drug Firdapse (amifampridine) from virtually ...

In a strong start to FY'26, MOIL has reported its highest ever April performance, reinforcing its commitment to operational ...

Kesar Petroproducts Ltd today announced that it has started commercial production at its new fertiliser plant in Ratnagiri, ...

Mumbai: Global pharma major, Lupin Limited, has received approval from the United States Food and Drug Administration (U.S.